SRPK1 and neoplasm: Of note, up to 85.4% (41/48) stage II patients were grouped into high-SRPK1 group, while only 36.5% (27/74) stage I cases showed high-SRPK1 expression, indicating that SRPK1 was positively correlated with CESC tumor progression (P < 0.001, Table 1)